Key facts
- This page summarizes Farshad Guirakhoo's Form 4 filing for Vaxxinity, Inc..
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 29 Aug 2022, 16:45.
Farshad Guirakhoo - 13 Jan 2022 Form 4 Insider Report for Vaxxinity, Inc.
- Reporting relationship
- (Former) Chief Scientific Off.
- Issuer ticker
- N/A
- Reported as of
- 13 Jan 2022
- Net transaction value
- +$33,428
- SEC form
- 4
- Accepted by SEC
- 29 Aug 2022, 16:45:35 UTC
- Prior SEC filing
- 15 Nov 2021
- Next SEC filing
- 05 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rene Paula Molina, attorney-in-fact for Farshad Guirakhoo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Farshad Guirakhoo filed Form 4 for Vaxxinity, Inc. on 29 Aug 2022.
Change
- Previous filing in this sequence was filed on 15 Nov 2021.
- Current net transaction value: +$33,428.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VAXX
transaction
Class A common stock
Options Exercise
- Transaction value
- $5,700
- Shares
- +10,000
- Change %
- Price
- $0.5700*
- Shares after
- 10,000
- Date
- 13 Jan 2022
- Ownership
- Direct
VAXX
transaction
Class A common stock
Options Exercise
- Transaction value
- $11,400
- Shares
- +20,000
- Change %
- +100%
- Price
- $0.5700*
- Shares after
- 40,000
- Date
- 29 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
VAXX
transaction
Class A common stock
Options Exercise
- Transaction value
- $14,823
- Shares
- +26,005
- Change %
- +65%
- Price
- $0.5700*
- Shares after
- 66,005
- Date
- 15 Aug 2022
- Ownership
- Direct
VAXX
transaction
Class A common stock
Options Exercise
- Transaction value
- $1,505
- Shares
- +2,640
- Change %
- +4%
- Price
- $0.5700*
- Shares after
- 68,645
- Date
- 22 Aug 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VAXX
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -7.9%
- Price
- $0.000000
- Shares after
- 116,730
- Date
- 13 Jan 2022
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 10,000
- Exercise price
- $0.5700
- Footnotes
- F2
VAXX
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -19%
- Price
- $0.000000
- Shares after
- 86,730
- Date
- 29 Jul 2022
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 20,000
- Exercise price
- $0.5700
- Footnotes
- F2, F3
VAXX
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -26,005
- Change %
- -30%
- Price
- $0.000000
- Shares after
- 60,725
- Date
- 15 Aug 2022
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 26,005
- Exercise price
- $0.5700
- Footnotes
- F2
VAXX
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,640
- Change %
- -4.3%
- Price
- $0.000000
- Shares after
- 58,085
- Date
- 22 Aug 2022
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 2,640
- Exercise price
- $0.5700
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Farshad Guirakhoo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock.
Footnote F2
These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.
Footnote F3
The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options.